BioTech Annecto

biotechannecto.com

BioTech Annecto is a social networking organization, whose aim is to bring together entrepreneurs, investors, scientists, attorneys, journalists and other professionals in the biotechnology sector: pharmaceutical, healthcare and biomedical, cosmetics, and environment. Launched February 2009 in Montreal (Quebec, Canada), BioTech Annecto (previously known as BioTech Montreal) is inviting people, one Tuesday every month, from the Montreal biotechnology community to meet at trendy locations around town. Members come from the business world, from public agencies as well as academic institutions. This allows regular communication and exchanges between industry, the public sector and academia.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy, MedTech

NKGEN BIOTECH, INC. ANNOUNCES FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF SNK02, ALLOGENEIC NK CELL THERAPY PRODUCT CANDIDATE

globenewswire | August 29, 2023

news image

NKGen Biotech, Inc. a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer (“NK”) cell therapies, today announced the first patient has been dosed in a Phase I, multi-center, open-label, dose-escalation study evaluating its cryopreserved investigational allogeneic blood-derived NK cell therapy (“SNK02”). In October 2022, the Food and Drug Administration allowed NKGen&rsq...

Read More

Cell and Gene Therapy

PULMATRIX ANNOUNCES PATIENT DOSING COMPLETED FOR ITS NOVEL INHALED THERAPY PUR3100 FOR ACUTE MIGRAINE

Pulmatrix, Inc. | September 27, 2022

news image

Pulmatrix, Inc. a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced that all subjects have completed dosing in a Phase 1 trial evaluating PUR3100, a novel orally inhaled formulation of dihydroergotamine in healthy volunteers. Phase 1 data from this study is expected in Q4 2022. The Phase 1 trial has a double-dummy, double-blinded design to assesses the safety, to...

Read More

Medical

NAVIGATE BIOPHARMA SERVICES, INC. LAUNCHES NEW MULTIPLEX DIGITAL PCR ASSAY FOR COMPREHENSIVE QUANTIFICATION OF UP TO 5 DIFFERENT CAR-T TRANSGENES

PRNewswire | June 02, 2023

news image

During this year's AAPS National biotechnology conference, Navigate BioPharma Services, Inc., a Novartis subsidiary and a leading provider of innovative biomarker solutions for drug development, announced the launch of its new multiplex digital PCR assays for comprehensive quantification of multiple chimeric antigen receptor (CAR) T cells, a type of cancer immunotherapy that involves genetically modifying T cells to recognize and destroy certain cancers. These assays are based on the Q...

Read More

Diagnostics

MACROGENICS USES GENEDATA PROFILER TO IMPROVE IMMUNOTHERAPY DEVELOPMENT

MacroGenics, Genedata | April 20, 2021

news image

Genedata, the leading supplier of enterprise software solutions for biopharmaceutical R&D, revealed today a long-term collaboration agreement with MacroGenics, a biopharmaceutical firm and emerging pioneer in discovering and commercializing innovative immune-oncology therapeutics. The agreement provides MacroGenics access to Genedata Profiler® as well as consulting services to aid in the platform's accelerated adoption and integration into MacroGenics' R&D infrastructure.
Read More

news image

Cell and Gene Therapy, MedTech

NKGEN BIOTECH, INC. ANNOUNCES FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF SNK02, ALLOGENEIC NK CELL THERAPY PRODUCT CANDIDATE

globenewswire | August 29, 2023

NKGen Biotech, Inc. a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer (“NK”) cell therapies, today announced the first patient has been dosed in a Phase I, multi-center, open-label, dose-escalation study evaluating its cryopreserved investigational allogeneic blood-derived NK cell therapy (“SNK02”). In October 2022, the Food and Drug Administration allowed NKGen&rsq...

Read More
news image

Cell and Gene Therapy

PULMATRIX ANNOUNCES PATIENT DOSING COMPLETED FOR ITS NOVEL INHALED THERAPY PUR3100 FOR ACUTE MIGRAINE

Pulmatrix, Inc. | September 27, 2022

Pulmatrix, Inc. a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced that all subjects have completed dosing in a Phase 1 trial evaluating PUR3100, a novel orally inhaled formulation of dihydroergotamine in healthy volunteers. Phase 1 data from this study is expected in Q4 2022. The Phase 1 trial has a double-dummy, double-blinded design to assesses the safety, to...

Read More
news image

Medical

NAVIGATE BIOPHARMA SERVICES, INC. LAUNCHES NEW MULTIPLEX DIGITAL PCR ASSAY FOR COMPREHENSIVE QUANTIFICATION OF UP TO 5 DIFFERENT CAR-T TRANSGENES

PRNewswire | June 02, 2023

During this year's AAPS National biotechnology conference, Navigate BioPharma Services, Inc., a Novartis subsidiary and a leading provider of innovative biomarker solutions for drug development, announced the launch of its new multiplex digital PCR assays for comprehensive quantification of multiple chimeric antigen receptor (CAR) T cells, a type of cancer immunotherapy that involves genetically modifying T cells to recognize and destroy certain cancers. These assays are based on the Q...

Read More
news image

Diagnostics

MACROGENICS USES GENEDATA PROFILER TO IMPROVE IMMUNOTHERAPY DEVELOPMENT

MacroGenics, Genedata | April 20, 2021

Genedata, the leading supplier of enterprise software solutions for biopharmaceutical R&D, revealed today a long-term collaboration agreement with MacroGenics, a biopharmaceutical firm and emerging pioneer in discovering and commercializing innovative immune-oncology therapeutics. The agreement provides MacroGenics access to Genedata Profiler® as well as consulting services to aid in the platform's accelerated adoption and integration into MacroGenics' R&D infrastructure.
Read More